Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9H9D4
UPID:
ZN408_HUMAN
Alternative names:
PR domain zinc finger protein 17
Alternative UPACC:
Q9H9D4
Background:
Zinc finger protein 408, also known as PR domain zinc finger protein 17, plays a crucial role in transcriptional regulation. Its unique structure, characterized by the presence of zinc finger motifs, suggests a specific interaction with DNA, influencing gene expression patterns critical for cellular functions.
Therapeutic significance:
The protein is implicated in two significant retinal diseases: Vitreoretinopathy, exudative 6, and Retinitis pigmentosa 72. These conditions highlight the protein's importance in retinal development and maintenance, suggesting that targeting Zinc finger protein 408 could offer new avenues for therapeutic intervention in retinal disorders.